药明康德(02359) - 2022 - 年度业绩

Financial Performance - The company achieved a revenue of RMB 39,354.8 million for the year ended December 31, 2022, representing a year-on-year growth of 71.8%[4]. - The net profit attributable to shareholders was RMB 8,813.7 million, an increase of 72.9% compared to the previous year[4]. - The gross profit reached RMB 14,506.5 million, with a gross margin of 36.9%, slightly up from 36.1% in 2021[2]. - The adjusted net profit attributable to shareholders was RMB 9,399.3 million, marking an 83.2% increase from the previous year[2]. - The net profit for the year increased by 73.3% to RMB 8,902.6 million, with a net profit margin of 22.6%[28]. - Overall gross profit for the company increased by 75.5% to RMB 14,506.5 million in 2022, with a gross margin of 36.9%[16]. - The total comprehensive income for the year was RMB 9,195,719 thousand, compared to RMB 4,625,059 thousand in the previous year, indicating a growth of approximately 98%[116]. - The company reported a pre-tax profit of RMB 10,618,477 thousand for the year ended December 31, 2022[124]. - The total revenue for the year ended December 31, 2022, was RMB 39,354,778 thousand, representing an increase from RMB 22,902,385 thousand in the previous year, which is a growth of approximately 72%[115]. Revenue Breakdown - Revenue from US clients was RMB 25,884 million, a significant increase of 113% year-on-year[5]. - Revenue from new clients amounted to RMB 1,573 million, contributing to a total revenue from existing clients of RMB 37,781 million, which grew by 77%[5]. - The chemical business segment generated RMB 28,849.7 million, reflecting a remarkable growth of 104.8% year-on-year[7]. - The revenue from the top 20 global pharmaceutical companies was RMB 18,421 million, showing a substantial growth of 174% year-on-year[5]. - The TIDES business achieved a revenue of RMB 1.578 billion, representing a year-on-year growth of 337%, with the number of service molecules increasing by 91% to 189[9]. - The testing business generated revenue of RMB 5.719 billion, a 26.4% increase from RMB 4.525 billion in the same period last year, with laboratory analysis and testing services growing by 36.1%[10]. - The biology segment reported revenue of RMB 2.475 billion, up 24.7% from RMB 1.985 billion, with new molecular-related services growing by 90%[11]. - The cell and gene therapy CTDMO business achieved revenue of RMB 1.308 billion, a 27.4% increase from RMB 1.026 billion, with testing services growing by 36%[12]. Client and Market Expansion - The company added over 1,400 new clients, serving more than 5,950 active clients globally across 30 countries[4]. - The company is expanding its international presence with new bases planned in Singapore and a production facility underway in Middletown, Delaware, USA[62]. - The company hosted 7 online events during the reporting period, with a total registration of over 28,000 participants, including industry leaders and patients, focusing on major challenges and opportunities in the industry[63]. - The company completed 77 live broadcasts covering all five major business segments, reaching over 220,000 views across more than 20 countries and regions, including all 34 provincial-level administrative regions in China[63]. Investment and R&D - Research and development expenses rose by 71.3% to RMB 1,614.0 million in 2022, reflecting increased investment in new molecular types[23]. - The company plans to invest heavily in new molecular types such as PROTAC, oligonucleotide drugs, and gene therapy, aiming to enhance its service capabilities and seize new business opportunities[89]. - The company has established a comprehensive "end-to-end" drug development service platform, benefiting from the rapid growth of the global drug development outsourcing market[59]. - The company reported a total of 973 new molecules in its pipeline, including 1 commercialized molecule, with a cumulative total of 2,341 molecules, comprising 50 commercial projects and 57 in clinical phase III[9]. Financial Management and Liabilities - The company's net cash flow from operating activities for 2022 was RMB 10,229.7 million, an increase of 133.6% compared to 2021, driven by rapid revenue growth and improved operational efficiency[29]. - The net cash used in investing activities for 2022 was RMB 9,311.2 million, up 101.2% from 2021, primarily due to increased capital expenditures for projects in various cities and investments in joint ventures[30]. - The total liabilities as of December 31, 2022, amounted to RMB 17,763.7 million, up from RMB 16,369.9 million in 2021, with 40.8% being accounts payable and other payables[31]. - The debt-to-asset ratio as of December 31, 2022, was 27.5%, down from 29.7% in 2021, reflecting an increase in retained earnings and net assets[34]. - The company has no significant contingent liabilities as of December 31, 2022[34]. Dividend and Shareholder Returns - The company proposed a final dividend of RMB 8.9266 per 10 shares, subject to shareholder approval[3]. - The board proposed a profit distribution plan for the year ending December 31, 2022, with a cash dividend of RMB 8.9266 per 10 shares, totaling RMB 2,644,137,750.80 (including tax)[107]. - The proposed profit distribution plan for 2022 includes a total dividend payout of RMB 2,644,137,750.80, translating to a dividend of RMB 0.89266 per share, an increase from RMB 0.5174 per share in 2021[140]. Risks and Challenges - The company faces risks from potential declines in demand for pharmaceutical R&D services, which could negatively impact its business[92]. - Regulatory changes in the pharmaceutical R&D services industry pose a risk, as the company must adapt to evolving policies and regulations[93]. - Increased competition in the global pharmaceutical R&D services market could threaten the company's competitive advantages if it fails to enhance its R&D capabilities[94]. - The company is exposed to foreign exchange risk, particularly if the RMB appreciates significantly, which could increase costs and lead to a decrease in customer orders[99]. Corporate Governance - The board confirmed adherence to corporate governance codes, although there was a deviation regarding the separation of the roles of Chairman and CEO, which are currently held by the same individual[110]. - The audit committee, consisting of three independent non-executive directors, reviewed the financial statements and internal controls for the reporting period[112].